Zum Hauptinhalt springen

Press Releases and Ad-hoc Announcements

13. April 2023
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
PDF
04. April 2023
PR: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
PDF
24. März 2023
PR: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
PDF
16. Dezember 2022
PR: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
PDF
10. November 2022
PR: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
PDF
07. November 2022
PR: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
PDF
13. Oktober 2022
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
PDF
04. Oktober 2022
AH: Heidelberg Pharma AG Announces Adjustment of Guidance
PDF
09. September 2022
AH: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
PDF
30. August 2022
PR: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure
PDF